Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

By adminOctober 17, 2020Global News Feed

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.

View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

Recce Pharmaceuticals Completes Capital Raising of $27.95 Million

By adminOctober 17, 2020Global News Feed

Highlights:

See more here:
Recce Pharmaceuticals Completes Capital Raising of $27.95 Million

Guerbet: 2020 Half-year results

By adminOctober 17, 2020Global News Feed

2020 half-year results

Visit link:
Guerbet: 2020 Half-year results

Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA

By adminOctober 17, 2020Global News Feed

Simplify Disc overall success rate of 93.0% was superior to the ACDF control Simplify Disc overall success rate of 93.0% was superior to the ACDF control

View original post here:
Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA

Saniona announces outcome of warrant exercise

By adminOctober 17, 2020Global News Feed

PRESS RELEASE

Read the original here:
Saniona announces outcome of warrant exercise

One World Pharma Releases Investor Presentation

By adminOctober 17, 2020Global News Feed

Television Legend Montel Williams Joins Isiah Thomas During Live Q&A

Read the rest here:
One World Pharma Releases Investor Presentation

New incentive program for the Board of Directors of Orphazyme

By adminOctober 17, 2020Global News Feed

Orphazyme A/SCompany announcement                                                                                       No. 53/2020                                                                                                          Company Registration No. 32266355

Continue reading here:
New incentive program for the Board of Directors of Orphazyme

Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness

By adminOctober 17, 2020Global News Feed

Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020

View original post here:
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness

Parexel Announces Solution for EU Clinical Trials Information System Regulation

By adminOctober 17, 2020Global News Feed

Resource hub streamlines and simplifies application process for clinical trials within EU Resource hub streamlines and simplifies application process for clinical trials within EU

Visit link:
Parexel Announces Solution for EU Clinical Trials Information System Regulation

electroCore to Participate in the JMP Securities MedTech Bio Summit

By adminOctober 17, 2020Global News Feed

BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit, which is being held virtually October 1-2, 2020.

Excerpt from:
electroCore to Participate in the JMP Securities MedTech Bio Summit